Phio Pharmaceuticals Advances Skin Cancer Study with Positive Safety Monitoring Committee Recommendation

Phio Pharmaceuticals announced that its Safety Monitoring Committee recommended advancing its INTASYL PH-762 skin cancer study to the fourth dose escalation cohort. The Phase 1b clinical trial is evaluating the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The committee found that injections were well tolerated with no serious adverse events and no dose-limiting toxicities in the third cohort.